New treatments for metastatic melanoma

CMAJ. Canadian Medical Association Journal

Volumn 186, Issue 10, 2014, Pages 754-760

  Gedye, Craig ^a   Hogg, David ^a   Butler, Marcus ^a   Joshua, Anthony M ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BMS 936559; CORTICOSTEROID; DABRAFENIB; DACARBAZINE; INFLIXIMAB; IPILIMUMAB; LOPERAMIDE; MELANOMA VACCINE; NIVOLUMAB; PEMBROLIZUMAB; PROTEIN ANTIBODY; RAF PROTEIN; RAS PROTEIN; SELUMETINIB; STEROID; TOPICAL AGENT; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB;

ABDOMINAL DISCOMFORT; ALOPECIA; ARTHRALGIA; BLOATING; BRAF GENE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COLITIS; DEATH; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRY SKIN; FATIGUE; FEVER; GENE MUTATION; HAND FOOT SYNDROME; HEPATITIS; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSITIS; IMMUNOTHERAPY; INTESTINE PERFORATION; LIVER TOXICITY; MEK GENE; METASTATIC MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; ONCOGENE; OVERALL SURVIVAL; PERITONITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PNEUMONIA; PROGRESSION FREE SURVIVAL; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SURVIVAL RATE; THYROIDITIS;

COMBINED MODALITY THERAPY; HUMANS; MELANOMA; NEOPLASM METASTASIS; SKIN NEOPLASMS;

EID: 84904352325     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.130989     Document Type: Review

References (40)

1. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995;181:193-201.
2. Cebon J, Gedye C, John T, et al. Immunotherapy of advanced or metastatic melanoma. Clin Adv Hematol Oncol 2007;5:994-1006.
3. Halliday GM, Patel A, Hunt MJ, et al. Spontaneous regression of human melanoma/nonmelanoma skin cancer: association with infiltrating CD4+ T cells. World J Surg 1995;19:352-8.
4. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-47.
5. Bauer J, Büttner P, Murali R, et al. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res 2011;24:345-51.
6. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011;29:1239-46.
7. Jakob JA, Bassett RL Jr, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012;118:4014-23.
8. Omholt K, Grafström E, Kanter-Lewensohn L, et al. KIT pathway alterations in mucosal melanomas of the vulva and other sites. Clin Cancer Res 2011;17:3933-42.
9. Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011;29:2904-9.
10. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
11. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
12. Chapman PB, Hauschild A, Robert C, et al. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (VEM) with dacarbazine (DTIC) in previously untreated pa tients with BRAFV600E-mutated melanoma. 2012 ASCO Annual Meeting Proceedings. J Clin Oncol 2012;30(15 Suppl):8502.
13. Hauschild A, Grob JJ, Demidov LV, et al. Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAFV600E-mutated melanoma. 2012 ASCO Annual Meeting Proceedings. J Clin Oncol 2012;30(18 Suppl): LBA8500.
14. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003;100:8372-7.
15. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
16. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-20.
17. Lebbe C, Weber JS, Maio M, et al. Five-year survival rates for patients (PTS) with metastatic melanoma (MM) treated with ipilimumab (IPI) in phase II trials [abstract]. Proceedings of the 2012 European Oncology Congress; 2012 Sept. 28 to Oct. 2; Vienna, Austria. Ann Oncol 2012;23(Suppl 9):9053.
18. Berman D, Parker SM, Siegel J, et al. Blockade of cytotoxic Tlymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 2010;10:11.
19. Minor DR, Chin K, Kashani-Sabet M. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immunerelated colitis. Cancer Biother Radiopharm 2009;24:321-5.
20. Chin K, Ibrahim R, Berman D, et al. Treatment guidelines for the management of immune-related adverse events in patients treated with ipilimumab, an anti-CTLA4 therapy [abstract]. Ann Oncol 2008;19(Suppl 8):787.
21. Wilson TR, Fridlyand J, Yan Y, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012;487:505-9.
22. Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010;18:683-95.
23. Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011;29:3085-96.
24. Robert C, Schadendorf D, Messina M, et al.; MDX010-20 investigators. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res 2013;19:2232-9.
25. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-703.
26. Jaiswal BS, Janakiraman V, Kljavin NM, et al. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PLoS ONE 2009;4:e5717.
27. Ascierto PA, Berking C, Agarwala SS, et al. Efficacy and safety of oral MEK162 in patients with locally advanced and un resectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. 2012 ASCO Annual Meeting Proceedings. J Clin Oncol 2012;30(15 Suppl):8511.
28. Richard D, Carvajal JAS, Fernando Quevedo, et al. Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM). 2013 ASCO Annual Meeting Proceedings. J Clin Oncol 2013;31(18 Suppl):CRA9003.
29. Butler MO, Friedlander P, Milstein MI, et al. Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med 2011;3:80ra34.
30. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509-18.
31. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008;26:5233-9.
32. Besser MJ, Shapira-Frommer R, Itzhaki O, et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res 2013;19:4792-800.
33. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800.
34. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-75.
35. Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of Anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
36. Hodi FS, Sznol M, McDermott DF, et al. Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced melanoma (MEL). 2012 ASCO Annual Meeting Proceedings. J Clin Oncol 2012;30(15 Suppl):8507.
37. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
38. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44.
39. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33.
40. Ribas A, Hodi FS, Callahan M, et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013;368:1365-6.